Dots

Mutated IDH in AML

A Simple Concept for a Complex Disease

Sign up for Updates

Receive periodic updates and more information about IDH mutations and AML. *Required

dot dot dot dot dot dot dot
Based on a recent analysis of 200 patients with de novo AML.
AML, acute myeloid leukemia; IDH, isocitrate dehydrogenase.
References: 1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. 2. McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest.2013;123(9):3672-3677. 3. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567. 4. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2054. 5. Patel K, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135(1):35-45. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2016. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed November 11, 2016. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 7. ClinicalTrials.gov [database online]. Accessed August 3, 2016.